Company intelligence / Profile preview
BJ Bioscience Inc.
Hangzhou, Chinabjbioscience.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Phase 1
01
Overview
BJ-001, the company's lead asset, has demonstrated tolerable safety profiles, favorable PK/PD profiles, and encouraging preliminary efficacy results in monotherapy dose escalation cohorts. The company is currently evaluating BJ-001 in combination with MSD's KEYTRUDA in patients with locally advanced/metastatic solid tumors[4][6].
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Bispecific antibodiesMonoclonal antibodiesFusion proteins
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
MSD (Merck & Co., Inc.) for clinical trial collaboration to evaluate BJ-001 in combination with KEYTRUDA (pembrolizumab)[4]
Beyond the preview
Go deeper on BJ Bioscience Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BJ Bioscience Inc..